**Supplementary Table S2.** Clinical activity by PD-L1 status

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Parameter** | **Arm A****2L D+T** | **Arm B****2L D** | **Arm C****2L T** | **Arm D****3L D+T** | **Arm E****2L/3L D+T IFN-γ+** |
| **PD-L1****High****(*n* = 14)** | **PD-L1 Low/Neg****(*n* = 10)** | **PD-L1****High****(*n* = 9)** | **PD-L1 Low/Neg****(*n* = 11)** | **PD-L1****High****(*n* = 5)** | **PD-L1 Low/Neg****(*n* = 4)** | **PD-L1****High****(*n* = 5)** | **PD-L1 Low/Neg****(*n* = 15)** | **PD-L1****High****(*n* = 9)** | **PD-L1 Low/Neg****(*n* = 3)** |
| ORR, *n* (%)[95% CI]CRPRSDPDNE | 2 (14.3)[1.8–42.8]02 (14.3)08 (57.1)4 (28.6) | 0 [0–30.8]005 (50.0)5 (50.0)0 | 0[0–33.6]0005 (55.6)4 (44.4) | 0 [0–28.5]002 (18.2)7 (63.6)2 (18.2) | 0[0–45.9]001 (16.7)4 (66.7)1 (16.7) | 1 (25.0)[0.6–80.6]01 (25.0)1 (25.0)02 (50.0) | 0[0–52.2]0003 (60.0)2 (40.0) | 0 [0–21.8]006 (40.0)7 (46.7)2 (13.3) | 3 (33.3)[7.5–70.1]1 (11.1)2 (22.2)04 (44.4)2 (22.2) | 0[0.0–70.8]0003 (100)0 |
| Median PFS, months (95% CI) | 1.7(1.6–5.4) | 2.8(1.2–3.6) | 1.7(0.8–1.8) | 1.6(0.9–3.4) | 1.7(0.8–5.3) | 5.4 (0.8–7.7) | 1.5(1.0–1.8) | 2.1(1.6–3.6) | 1.8(1.0–4.9) | 1.8(1.8–1.9) |
| PFS-6, % (95% CI) | 12.7 (0.9–40.3) | 0 (NA–NA) | 0(0-0) | 0(NA–NA) | 0(0-0) | 50.0(5.8–84.5) | 0(0–0) | 16.7(2.9–40.2) | 0(NA–NA) | 0(0–0) |
| Median OS, months (95% CI) | 10.6(5.4–15.4) | 8.9(2.0–12.6) | 2.9 (0.8–7.0) | 3.6(1.2–4.4) | 10.8 (3.1–NA) | 5.6(0.8–10.5) | 4.8 (1.0–21.0) | 10.6(2.3–12.8) | 7.0(1.4–NA) | NA(2.4–NA) |
| OS-12, % (95% CI) | 42.9(17.7–66.0) | 30.0(7.1–57.8) | 0(0–0) | 9.1(0.5–33.3) | 50 (5.8–84.5) | 0(0–0) | 26.7 (1.0–68.6) | 29.6(9.3–53.6) | 0(NA–NA) | 0(NA–NA) |
| OS-24, % (95% CI) | 21.4 (5.2–44.8) | 20.0(3.1–47.5) | 0(0–0) | 0(0–0) | 25 (0.9–66.5) | 0(0–0) | 0(0–0) | 7.4(0.5–28.3) | 0(NA–NA) | 0(NA–NA) |

2L = received treatment in the second-line setting; 3L = received treatment in the third-line setting; CI = confidence interval; D = durvalumab; NA = not applicable; Neg = negative; ORR = objective response rate; OS = overall survival; PD-L1 = programmed cell death ligand 1; PFS = progression-free survival; T = tremelimumab.

**Supplementary Table S2.** Clinical activity by PD-L1 status

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Parameter** | **Arm A****2L D+T** | **Arm B****2L D** | **Arm C****2L T** | **Arm D****3L D+T** | **Arm E****2L/3L D+T IFN-γ+** |
| **PD-L1****High****(*n* = 14)** | **PD-L1 Low/Neg****(*n* = 10)** | **PD-L1****High****(*n* = 9)** | **PD-L1 Low/Neg****(*n* = 11)** | **PD-L1****High****(*n* = 5)** | **PD-L1 Low/Neg****(*n* = 4)** | **PD-L1****High****(*n* = 5)** | **PD-L1 Low/Neg****(*n* = 15)** | **PD-L1****High****(*n* = 9)** | **PD-L1 Low/Neg****(*n* = 3)** |
| ORR, *n* (%)[95% CI]CRPRSDPDNE | 2 (14.3)[1.8–42.8]02 (14.3)08 (57.1)4 (28.6) | 0 [0–30.8]005 (50.0)5 (50.0)0 | 0[0–33.6]0005 (55.6)4 (44.4) | 0 [0–28.5]002 (18.2)7 (63.6)2 (18.2) | 0[0–45.9]001 (16.7)4 (66.7)1 (16.7) | 1 (25.0)[0.6–80.6]01 (25.0)1 (25.0)02 (50.0) | 0[0–52.2]0003 (60.0)2 (40.0) | 0 [0–21.8]006 (40.0)7 (46.7)2 (13.3) | 3 (33.3)[7.5–70.1]1 (11.1)2 (22.2)04 (44.4)2 (22.2) | 0[0.0–70.8]0003 (100)0 |
| Median PFS, months (95% CI) | 1.7(1.6–5.4) | 2.8(1.2–3.6) | 1.7(0.8–1.8) | 1.6(0.9–3.4) | 1.7(0.8–5.3) | 5.4 (0.8–7.7) | 1.5(1.0–1.8) | 2.1(1.6–3.6) | 1.8(1.0–4.9) | 1.8(1.8–1.9) |
| PFS-6, % (95% CI) | 12.7 (0.9–40.3) | 0 (NA–NA) | 0(0-0) | 0(NA–NA) | 0(0-0) | 50.0(5.8–84.5) | 0(0–0) | 16.7(2.9–40.2) | 0(NA–NA) | 0(0–0) |
| Median OS, months (95% CI) | 10.6(5.4–15.4) | 8.9(2.0–12.6) | 2.9 (0.8–7.0) | 3.6(1.2–4.4) | 10.8 (3.1–NA) | 5.6(0.8–10.5) | 4.8 (1.0–21.0) | 10.6(2.3–12.8) | 7.0(1.4–NA) | NA(2.4–NA) |
| OS-12, % (95% CI) | 42.9(17.7–66.0) | 30.0(7.1–57.8) | 0(0–0) | 9.1(0.5–33.3) | 50 (5.8–84.5) | 0(0–0) | 26.7 (1.0–68.6) | 29.6(9.3–53.6) | 0(NA–NA) | 0(NA–NA) |
| OS-24, % (95% CI) | 21.4 (5.2–44.8) | 20.0(3.1–47.5) | 0(0–0) | 0(0–0) | 25 (0.9–66.5) | 0(0–0) | 0(0–0) | 7.4(0.5–28.3) | 0(NA–NA) | 0(NA–NA) |

2L = received treatment in the second-line setting; 3L = received treatment in the third-line setting; CI = confidence interval; D = durvalumab; NA = not applicable; Neg = negative; ORR = objective response rate; OS = overall survival; PD-L1 = programmed cell death ligand 1; PFS = progression-free survival; T = tremelimumab.